162011-83-8

Basic information

• Product Name: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone
• Synonyms: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone;4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2H-furan-5-one
• CAS NO: 162011-83-8
• Molecular Formula: C₁₇H₁₂F₂O₄S
• Molecular Weight: 350.3366
• Mol File: 162011-83-8.mol

Chemical Properties

• Boiling Point: 575.8°Cat760mmHg
• Flash Point: 302°C
• Appearance: /
• Density: 1.435g/cm³
• Vapor Pressure: 2.94E-13mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(162011-83-8)
• EPA Substance Registry System: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(162011-83-8)

Safety Data

• Hazardous Substances Data: 162011-83-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H12F2O4S/c1-24(21,22)12-5-2-10(3-6-12)13-9-23-17(20)16(13)11-4-7-14(18)15(19)8-11/h2-8H,9H2,1H3

Upstream product

• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 121-44-8 triethylamine 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 

Downstream Products

• 179174-83-5 (2Z)-4-(acetoxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoic acid 
• 179174-80-2 (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol 
• 851609-10-4 2-(3,4-difluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-but-2-ene-1,4-diol 
• 179174-81-3 (2Z)-3-(3,4-difluorophenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl acetate 
• 179174-82-4 (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenal 

Relevant articles and documents

Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia

A water soluble choline prodrug (17) of a COX-2 selective inhibitor (16) suitable for intravenous dosing in models of cerebral ischemia has been developed. Constant infusion studies using 17 demonstrate that extrapolated brain levels of 16 may be maintained for over 24 h in rats.

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor

This invention relates to the use of a tocolytic agent or agents in combination with selective cyclooxygenase-2 inhibitors of Formula (II) or a pharmaceutically-acceptable salt or derivative thereof for preparing a medicament for maintaining circulation through fetal ductus arteriosus during treatment or prevention of preterm labor in a subject in need of such treatment or prevention.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and an NSAID compound, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and an NSAID compound. The invention also relates to methods of preparing such compositions.

Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

A method to suppress immune, acute or delayed-type hypersensitivity by treatment with a combination of a therapeutically-effective amount of a 5-lipoxygenase inhibitor and a cyclooxygenase-2 inhibitor is reported. The method may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A4hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmnune diseases.

IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST

Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B 4 receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.

Method of treating colonic adenomas

This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

Phenyl heterocycles as cox-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases

The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: STR1

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.